In this section we usually present revenue and earnings growth
projections based on the consensus estimates of professional
analysts to help investors understand the company’s ability to
generate profit. But as BIOTON has not provided enough
past data and has no analyst forecast, its future earnings
cannot be reliably calculated by extrapolating past data or
using analyst predictions.
This is quite a rare situation as 97% of companies covered by
SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
WSE:BIO - Analysts future estimates and past financials data (PLN Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2025
283
3
10
23
N/A
9/30/2025
296
-3
24
32
N/A
6/30/2025
265
-10
23
32
N/A
3/31/2025
236
-16
23
33
N/A
12/31/2024
208
-16
25
36
N/A
9/30/2024
178
-6
13
38
N/A
6/30/2024
186
-7
21
54
N/A
3/31/2024
185
-3
6
51
N/A
12/31/2023
182
2
-5
40
N/A
9/30/2023
212
2
-4
31
N/A
6/30/2023
218
4
3
37
N/A
3/31/2023
217
4
18
50
N/A
12/31/2022
233
1
27
56
N/A
9/30/2022
197
-4
40
61
N/A
6/30/2022
188
3
19
39
N/A
3/31/2022
176
5
-2
8
N/A
12/31/2021
163
3
-7
6
N/A
9/30/2021
212
22
-8
-1
N/A
6/30/2021
208
20
-5
-5
N/A
3/31/2021
222
23
28
31
N/A
12/31/2020
222
34
37
42
N/A
9/30/2020
185
-24
24
45
N/A
6/30/2020
186
-34
41
77
N/A
3/31/2020
208
-148
12
59
N/A
12/31/2019
202
-127
-7
47
N/A
9/30/2019
209
-98
N/A
64
N/A
6/30/2019
213
-109
N/A
9
N/A
3/31/2019
226
76
N/A
11
N/A
12/31/2018
241
26
N/A
28
N/A
9/30/2018
294
29
N/A
1
N/A
6/30/2018
337
47
N/A
35
N/A
3/31/2018
338
-39
N/A
23
N/A
12/31/2017
362
-27
N/A
2
N/A
9/30/2017
303
-31
N/A
3
N/A
6/30/2017
286
-31
N/A
-14
N/A
3/31/2017
279
-28
N/A
9
N/A
12/31/2016
278
-16
N/A
23
N/A
9/30/2016
251
-536
N/A
33
N/A
6/30/2016
289
-526
N/A
39
N/A
3/31/2016
308
-522
N/A
15
N/A
12/31/2015
333
-522
N/A
24
N/A
9/30/2015
417
14
N/A
36
N/A
6/30/2015
411
10
N/A
43
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if BIO's forecast earnings growth is above the savings rate (5.3%).
Earnings vs Market: Insufficient data to determine if BIO's earnings are forecast to grow faster than the Polish market
High Growth Earnings: Insufficient data to determine if BIO's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if BIO's revenue is forecast to grow faster than the Polish market.
High Growth Revenue: Insufficient data to determine if BIO's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BIO's Return on Equity is forecast to be high in 3 years time
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/20 16:49
End of Day Share Price
2026/05/20 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BIOTON S.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.